These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34177942)

  • 21. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
    Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interplay between inflammation and thrombosis in cardiovascular pathology.
    Stark K; Massberg S
    Nat Rev Cardiol; 2021 Sep; 18(9):666-682. PubMed ID: 33958774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Role of the Podoplanin-CLEC-2 Axis in Promoting Inflammatory Response After Ischemic Stroke in Mice.
    Meng D; Ma X; Li H; Wu X; Cao Y; Miao Z; Zhang X
    Neurotox Res; 2021 Apr; 39(2):477-488. PubMed ID: 33165736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A role of platelet C-type lectin-like receptor-2 and its ligand podoplanin in vascular biology.
    Suzuki-Inoue K; Tsukiji N
    Curr Opin Hematol; 2024 May; 31(3):130-139. PubMed ID: 38359177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice.
    Shirai T; Inoue O; Tamura S; Tsukiji N; Sasaki T; Endo H; Satoh K; Osada M; Sato-Uchida H; Fujii H; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2017 Mar; 15(3):513-525. PubMed ID: 28028907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal cells activate the platelet receptor CLEC-2 through podoplanin.
    Christou CM; Pearce AC; Watson AA; Mistry AR; Pollitt AY; Fenton-May AE; Johnson LA; Jackson DG; Watson SP; O'Callaghan CA
    Biochem J; 2008 Apr; 411(1):133-40. PubMed ID: 18215137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.
    Bianchi R; Fischer E; Yuen D; Ernst E; Ochsenbein AM; Chen L; Otto VI; Detmar M
    J Biol Chem; 2014 Jul; 289(30):21016-27. PubMed ID: 24907275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
    Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
    Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2.
    Herzog BH; Fu J; Wilson SJ; Hess PR; Sen A; McDaniel JM; Pan Y; Sheng M; Yago T; Silasi-Mansat R; McGee S; May F; Nieswandt B; Morris AJ; Lupu F; Coughlin SR; McEver RP; Chen H; Kahn ML; Xia L
    Nature; 2013 Oct; 502(7469):105-9. PubMed ID: 23995678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel platelet activation receptor CLEC-2: from discovery to prospects.
    Suzuki-Inoue K; Inoue O; Ozaki Y
    J Thromb Haemost; 2011 Jul; 9 Suppl 1():44-55. PubMed ID: 21781241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets.
    Suzuki-Inoue K; Inoue O; Ding G; Nishimura S; Hokamura K; Eto K; Kashiwagi H; Tomiyama Y; Yatomi Y; Umemura K; Shin Y; Hirashima M; Ozaki Y
    J Biol Chem; 2010 Aug; 285(32):24494-507. PubMed ID: 20525685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice.
    Tsukiji N; Osada M; Sasaki T; Shirai T; Satoh K; Inoue O; Umetani N; Mochizuki C; Saito T; Kojima S; Shinmori H; Ozaki Y; Suzuki-Inoue K
    Blood Adv; 2018 Sep; 2(17):2214-2225. PubMed ID: 30190281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes.
    Tanaka K; Tanaka M; Watanabe N; Ito M; Pastan I; Koizumi M; Matsusaka T
    Sci Rep; 2022 Dec; 12(1):22356. PubMed ID: 36572741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional significance of the platelet immune receptors GPVI and CLEC-2.
    Rayes J; Watson SP; Nieswandt B
    J Clin Invest; 2019 Jan; 129(1):12-23. PubMed ID: 30601137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
    Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
    J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Identification of the novel platelet activation receptor CLEC-2 and Its pathological and physiological roles].
    Suzuki Inoue K; Inoue O; Ozaki Y
    Rinsho Byori; 2010 Dec; 58(12):1193-202. PubMed ID: 21348239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model.
    Shirai T; Tsukiji N; Sasaki T; Oishi S; Yokomori R; Takano K; Suzuki-Inoue K
    J Thromb Haemost; 2023 Nov; 21(11):3153-3165. PubMed ID: 37473844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI.
    Watanabe N; Shinozaki Y; Ogiwara S; Miyagasako R; Sasaki A; Kato J; Suzuki Y; Fukunishi N; Okada Y; Saito T; Iida Y; Higashiseto M; Masuda H; Nagata E; Gotoh K; Amino M; Tsuji T; Morita S; Nakagawa Y; Hirayama N; Inokuchi S
    Thromb Haemost; 2024 Mar; 124(3):203-222. PubMed ID: 37967855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin.
    Nagae M; Morita-Matsumoto K; Kato M; Kaneko MK; Kato Y; Yamaguchi Y
    Structure; 2014 Dec; 22(12):1711-1721. PubMed ID: 25458834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis.
    Payne H; Ponomaryov T; Watson SP; Brill A
    Blood; 2017 Apr; 129(14):2013-2020. PubMed ID: 28104688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.